Crossmark

1058 Optimal antitumor immunity triggered by WTX-124, a clinical stage conditionally activated INDUKINE<sup>TM</sup> molecule that releases fully potent IL-2 in the tumor microenvironment

Crossref DOI link: https://doi.org/10.1136/jitc-2023-SITC2023.1058

Published Online: 2023-11-02

Published Print: 2023-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Nirschl, Christopher J

Brodkin, Heather R

Hicklin, Daniel J

Ismail, Nesreen

Lewis, Yuka

Seidel-Dugan, Cynthia

Steuert, Zoe

Sullivan, Jenna M

Winston, William M

Salmeron, Andres
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct05678998 at ClinicalTrials.gov

Documents that mention this clinical trial

1058 Optimal antitumor immunity triggered by WTX-124, a clinical stage conditionally activated INDUKINE<sup>TM</sup> molecule that releases fully potent IL-2 in the tumor microenvironment
https://doi.org/10.1136/jitc-2023-sitc2023.1058
License Information

License valid from 2023-10-21

Document is current

Any future updates will be listed below